Invention Grant
- Patent Title: Polypeptides inhibiting CD40L
-
Application No.: US15778677Application Date: 2016-11-28
-
Publication No.: US11248055B2Publication Date: 2022-02-15
- Inventor: Els Pattyn , Ariëlla Van de Sompel , Peter Meerts , Marie-Ange Buyse , Maarten Dewilde , Gerald Beste , Jaromir Vlach , Jonathan Hsu
- Applicant: Ablynx N.V.
- Applicant Address: BE Ghent-Zwijnaarde
- Assignee: Ablynx N.V.
- Current Assignee: Ablynx N.V.
- Current Assignee Address: BE Ghent-Zwijnaarde
- Agency: Wolf, Greenfield & Sacks, P.C.
- International Application: PCT/EP2016/079048 WO 20161128
- International Announcement: WO2017/089618 WO 20170601
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; C07K16/18 ; A61K39/00
Abstract:
The present invention relates to immunoglobulins that specifically bind CD40L and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of CD40L and are safe.
Public/Granted literature
- US20180355050A1 POLYPEPTIDES INHIBITING CD40L Public/Granted day:2018-12-13
Information query
